RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

AUPH

0.00

RBC Capital analyst Douglas Miehm maintains Aurinia Pharmaceuticals (NASDAQ: AUPH) with a Sector Perform and raises the price target from $15 to $16.